The EGFR (epidermal growth factor receptor)-targeted drugs, gefitinib (Iressa) and erlotinib (Tarceva) were evaluated in esophageal cancer in phase II and phase III studies [42–45]. This evidence concerns the gene EGFR and esophageal cancer.